Table of Contents

March 1, 2022; Volume 63,Issue 3

  1. Aarntzen, Erik H.J.G.

    1. Toward a Better Understanding of Immune Checkpoint Inhibitor Radiolabeled PET Imaging Studies
      Harm Westdorp, Sarah R. Verhoeff, Martin Gotthardt, Carla M.L. van Herpen, Michel M. van, den Heuvel, Sandra Heskamp and Erik H.J.G. Aarntzen
      Journal of Nuclear Medicine March 1, 2022, 63 (3) 359-361; DOI: https://doi.org/10.2967/jnumed.121.262622

  2. Addeo, Pietro

    1. Value of <sup>68</sup>Ga-DOTATOC and Carbidopa-Assisted <sup>18</sup>F-DOPA PET/CT for Insulinoma Localization
      Value of 68Ga-DOTATOC and Carbidopa-Assisted 18F-DOPA PET/CT for Insulinoma Localization
      Alessio Imperiale, Caroline Boursier, Nicolas Sahakian, Eric Ouvrard, Elodie Chevalier, Frédéric Sebag, Pietro Addeo and David Taïeb
      Journal of Nuclear Medicine March 1, 2022, 63 (3) 384-388; DOI: https://doi.org/10.2967/jnumed.121.262401

  3. Afshar-oromieh, Ali

    1. Performance Characteristics of the Biograph Vision Quadra PET/CT System with a Long Axial Field of View Using the NEMA NU 2-2018 Standard
      Performance Characteristics of the Biograph Vision Quadra PET/CT System with a Long Axial Field of View Using the NEMA NU 2-2018 Standard
      George A. Prenosil, Hasan Sari, Markus Fürstner, Ali Afshar-Oromieh, Kuangyu Shi, Axel Rominger and Michael Hentschel
      Journal of Nuclear Medicine March 1, 2022, 63 (3) 476-484; DOI: https://doi.org/10.2967/jnumed.121.261972

  4. Akesson, Anna

    1. Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with <sup>177</sup>Lu-DOTATATE
      Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with 177Lu-DOTATATE
      Daniel Roth, Johan Gustafsson, Carl Fredrik Warfvinge, Anna Sundlöv, Anna Åkesson, Jan Tennvall and Katarina Sjögreen Gleisner
      Journal of Nuclear Medicine March 1, 2022, 63 (3) 399-405; DOI: https://doi.org/10.2967/jnumed.121.262069

  5. Almaguel, Frankis

    1. Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using <sup>177</sup>Lu-FAP-2286: First-in-Humans Results
      Open Access
      Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results
      Richard P. Baum, Christiane Schuchardt, Aviral Singh, Maythinee Chantadisai, Franz C. Robiller, Jingjing Zhang, Dirk Mueller, Alexander Eismant, Frankis Almaguel, Dirk Zboralski, Frank Osterkamp, Aileen Hoehne, Ulrich Reineke, Christiane Smerling and Harshad R. Kulkarni
      Journal of Nuclear Medicine March 1, 2022, 63 (3) 415-423; DOI: https://doi.org/10.2967/jnumed.120.259192

  6. Bahce, Idris

    1. Study of <sup>89</sup>Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non–Small Cell Lung Cancer
      Study of 89Zr-Pembrolizumab PET/CT in Patients With Advanced-Stage Non–Small Cell Lung Cancer
      Anna-Larissa N. Niemeijer, Daniela E. Oprea-Lager, Marc C. Huisman, Otto S. Hoekstra, Ronald Boellaard, Berlinda J. de Wit-van der Veen, Idris Bahce, Daniëlle J. Vugts, Guus A.M.S. van Dongen, Erik Thunnissen, Egbert F. Smit and Adrianus J. de Langen
      Journal of Nuclear Medicine March 1, 2022, 63 (3) 362-367; DOI: https://doi.org/10.2967/jnumed.121.261926

  7. Bahri, Shadfar

    1. A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for <sup>68</sup>Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors
      Open Access
      A Randomized, Factorial Phase II Study to Determine the Optimal Dosing Regimen for 68Ga-Satoreotide Trizoxetan as an Imaging Agent in Patients with Gastroenteropancreatic Neuroendocrine Tumors
      Irene Virgolini, Shadfar Bahri, Andreas Kjaer, Henning Grønbæk, Peter Iversen, Esben A. Carlsen, Mathias Loft, Ulrich Knigge, Johanna Maffey-Steffan, Christine Powell, Colin G. Miller, Thomas Rohban, Sandy McEwan and Johannes Czernin
      Journal of Nuclear Medicine March 1, 2022, 63 (3) 376-383; DOI: https://doi.org/10.2967/jnumed.121.261936

  8. Banerjee, Indraneel

    1. 68Ga-NODAGA-Exendin-4 PET Scanning for Focal Congenital Hyperinsulinism: Need for Replication
      Indraneel Banerjee, Rakesh Sajjan, Maria Salomon Estebanez, Mark J. Dunne, Konrad Mohnike, Wolfgang Mohnike, Lisa J. States, Diva D. De Leon and Klaus Mohnike
      Journal of Nuclear Medicine March 1, 2022, 63 (3) 493; DOI: https://doi.org/10.2967/jnumed.121.262984

  9. Barca, Cristina

    1. A Longitudinal PET/MRI Study of Colony-Stimulating Factor 1 Receptor–Mediated Microglia Depletion in Experimental Stroke
      Open Access
      A Longitudinal PET/MRI Study of Colony-Stimulating Factor 1 Receptor–Mediated Microglia Depletion in Experimental Stroke
      Cristina Barca, Amanda J. Kiliaan, Claudia Foray, Lydia Wachsmuth, Sven Hermann, Cornelius Faber, Michael Schäfers, Maximilian Wiesmann, Andreas H. Jacobs and Bastian Zinnhardt
      Journal of Nuclear Medicine March 1, 2022, 63 (3) 446-452; DOI: https://doi.org/10.2967/jnumed.121.262279

  10. Baum, Richard P.

    1. Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using <sup>177</sup>Lu-FAP-2286: First-in-Humans Results
      Open Access
      Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results
      Richard P. Baum, Christiane Schuchardt, Aviral Singh, Maythinee Chantadisai, Franz C. Robiller, Jingjing Zhang, Dirk Mueller, Alexander Eismant, Frankis Almaguel, Dirk Zboralski, Frank Osterkamp, Aileen Hoehne, Ulrich Reineke, Christiane Smerling and Harshad R. Kulkarni
      Journal of Nuclear Medicine March 1, 2022, 63 (3) 415-423; DOI: https://doi.org/10.2967/jnumed.120.259192
« Previous (Pages : 1 2 3 4 5 6 ... 22) Next »
Back to top

In this issue